Dazukibart
Sponsors
Pfizer Inc., Pfizer
Conditions
Active Idiopathic Inflammatory Myopathies (Including Dermatomyositis or Polymyositis)DermatomyositisIdiopathic Inflammatory Myopathy (including dermatomyositis or polymyositis)Polymyositis
Phase 3
C0251006 - A PHASE 3, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES (INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS)
RecruitingCTIS2022-502739-20-00
Start: 2023-11-16Target: 79Updated: 2025-12-17
A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
RecruitingNCT06698796
Start: 2025-01-22End: 2027-11-25Target: 211Updated: 2026-03-27
C0251010 - A PHASE 3, MULTI-CENTER, OPEN-LABEL EXTENSION STUDY TO INVESTIGATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF DAZUKIBART IN PARTICIPANTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES (INCLUDING PARTICIPANTS WITH DERMATOMYOSITIS OR POLYMYOSITIS)
RecruitingCTIS2024-514648-10-00
Start: 2025-03-14Target: 21Updated: 2025-11-25